Keywords: Alimera Sciences, Iluvien, Xencor, Xtend, Janssen, Antibody, Galapagos, Milestone, Cangenix, M&A

News briefs from Alimera on Iluvien and Xencor on Xtend; Galapagos milestone and acquisition

Article | 17 January 2013

Print This

US biopharma company Alimera Sciences (Nasdaq: ALIM) says that the Spanish Agency of Drugs and Medical Devices has granted marketing ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in